996.2500 31.85 (3.30%)
NSE Apr 09, 2026 15:31 PM
Volume: 264.9K
 

996.25
3.30%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd. is trading above all available SMAs
More from Strides Pharma Science Ltd.
Recommended